Simultaneous administration of Hepatitis B vaccine with other E.P.I. vaccines
- 34 Downloads
Development of recombinant DNA vaccine against hepatitis B grown on cultured yeast cell has made it possible to mount a world-wide effort to control and eradicate Hepatitis B infection. However, the currently recommended schedules (0, 1 & 2 months, and 0–1 and 6 months) do not coincide with the scheduled visits for other E.P.I. vaccines, and necessitate additional visits for Hepatitis B vaccination. This study was therefore carried out to find out if adequate seroconversion occurs to Hepatitis B vaccine when given with other EPI vaccines or not?
Thirty nine infants born to Australia antigen positive mothers from among 850 screened pregnant mothers were recruited to receive Hepatitis B vaccine (Engerix B-10 micro gram each) at 0, 6 and 14 wks (group A) or at 0, 1 and 2 months (group B). Thirty-one infants were recruited in group A and 8 in group B. The cord blood was collected and the first dose of vaccine was given within 48 hours of birth. Simultaneous B.C.G. was given at the left deltoid. Other E.P.I. vaccines were given qt 6, 10 and 14 wks in group A and at 2, 3 and 4 months in group B. Repeat blood samples were collected prior to giving each dose of Hepatitis B vaccine, and 4 weeks after the last dose. All blood samples were assayed for HBsAg and HBsAb at the National Institute Of Communicable Diseases, utilizing standard ELISA kits.
The seroconversion rates following one, two and three doses of Hepatitis B vaccine were 3.33%, 55.5%, 96.15% and 0%, 62.5% and 100% in group A and B respectively. Only one infant in group A failed to develop HbsAb even after 3 doses of Hepatitis B vaccine, 5 infants in group A were available at 9 months of age and were still positive for HBsAb and negative for HBsAg. Recombinant DNA Hepatitis B vaccine (Engerix-B) is a highly effective vaccine which can safely and effectively be given together with other childhood vaccines.
Key wordsHepatitis B Vertical transmission Post exposure prophylaxis E.P.I.
Unable to display preview. Download preview PDF.
- 1.Ghendon Y. WHO strategy for the global elimination of new cases of Hepatitis B.Vaccine 1990; 8 (Suppl): 129–132.Google Scholar
- 5.Sung JL. Hepatitis B virus eradication strategy for Asia.Vaccine 1990; 8 (Suppl): 95–98.Google Scholar
- 8.Andre FE, Safary A. Summary of clinical findings on Engerix B, a genetically engineered yeast derived Hepatitis B vaccine.Post Grad Med J 1987; 63 (2): 169–178.Google Scholar
- 9.Centres for Diseases Control. Update on Hepatitis B prevention. Recommendations of the immunization practices advisory committee.Ann Intern Med 1987; 107: 353–357.Google Scholar
- 10.Maynard JE, Kane MA, Hadler SC. Global control of Hepatitis B through vaccination—Role of Hepatitis B vaccine in EPI.Rev Infect Dis 1989; 11 (Suppl 3): 574–578.Google Scholar
- 11.Expanded Programme on Immunization Cost-effectiveness.Weekly Epidemiology Record 1982; 22: 170–172.Google Scholar
- 13.Gupta I, Sehgal A, Bhakoo DN et al. Immunoprophylaxis of neonates born to Hepatitis B surface antigen positive pregnant women. Proceedings “Update in Viral Hepatitis” 1990; 137–143.Google Scholar
- 17.Cadranel S, Zeghlache S, Fernandes S et al. Vaccination of newborns of HBsAg positive carrier mothers with a recombinant DNA Hepatitis B caccine.Post Grad Med J 1987; 63 (Suppl 2): 159–160.Google Scholar
- 19.Memorandum from a WHO meeting. Progress in control of viral Hepatitis.Bull WHO 1988; 66: 443–455.Google Scholar